• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sema4 Holdings Corp. - Class A Common Stock (NQ:SMFR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.3150 (250)
Ask (Size) 0.3200 (78)
Prev. Close 0.3106
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sema4 Holdings Corp. (NASDAQ: SMFR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
February 08, 2023
San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary... 
Via SBWire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga

Performance

More News

Read More
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
January 09, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
Sema4 Holdings's Return on Invested Capital Overview
December 26, 2022
Via Benzinga
What To Know About Goldman Sachs's Downgrade of Sema4 Holdings
December 07, 2022
Via Benzinga
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 30, 2022
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
December 29, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
December 09, 2022
Via Benzinga
ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday
December 07, 2022
Via Benzinga
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
December 05, 2022
From Sema4
Via GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 14, 2022
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
Via Benzinga
NASDAQ:SMFR Investor Alert: Deadline on November 7, 2022 in Lawsuit Against Sema4 Holdings Corp.
November 09, 2022
Via SBWire
Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate
November 07, 2022
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
November 17, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 16, 2022
Via Benzinga
SMFR FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
November 07, 2022
Via NewMediaWire
Topics Lawsuit
Earnings Scheduled For November 14, 2022
November 14, 2022
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
November 06, 2022
From Bragar Eagel & Squire
Via GlobeNewswire
SMFR FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
November 06, 2022
Via NewMediaWire
Topics Lawsuit
SEMA4 HOLDINGS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Sema4 Holdings Corp. - SMFR
November 04, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
November 04, 2022
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
October 31, 2022
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Sema4 Holdings Corp. - Class A Common Stock publicly traded?
Yes, Sema4 Holdings Corp. - Class A Common Stock is publicly traded.
What exchange does Sema4 Holdings Corp. - Class A Common Stock trade on?
Sema4 Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sema4 Holdings Corp. - Class A Common Stock?
The ticker symbol for Sema4 Holdings Corp. - Class A Common Stock is SMFR on the Nasdaq Stock Market
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap